Cargando…

PB2007: INTEGRATION OF TELEHEALTH IN DAILY CLINICAL PRACTICE IN PATIENTS WITH MYELODYSPLASTIC NEOPLASMS - STATUS QUO AND FUTURE PERSPECTIVES

Detalles Bibliográficos
Autores principales:	Stauder, Reinhard, Lühring, Adrian, Tipelius, Stefanie, Rumpold, Gerhard, Künstner, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430245/ http://dx.doi.org/10.1097/01.HS9.0000974844.63868.0f

Ejemplares similares

PB2672: EXPLORING UNMET NEEDS OF PATIENTS WITH MYELODYSPLASTIC NEOPLASMS AND CAREGIVERS IN A NATIONAL ITALIAN SURVEY
por: Crisà, Elena, et al.
Publicado: (2023)

PB1997: TRISOMY 18 IN MYELODYSPLASTIC SYNDROMES
por: Abdelmoula, Nouha Bouayed, et al.
Publicado: (2023)

PB2015: DIAGNOSIS, CLASSIFICATION AND STRATIFICATION OF MYELODYSPLASTIC SYNDROMES IN ALGERIA
por: Moussa, Yamina Bouchakour, et al.
Publicado: (2023)

PB2020: OUTCOMES OF PATIENTS WITH HIGH RISK MYELODYSPLASTIC SYNDROMES
por: Amor, Imen Ben, et al.
Publicado: (2023)

PB2025: CULTURAL DATA TO NEW CLASSIFICATION OF MYELODYSPLASTIC NEOPLASIA
por: Saralidze, Tamar, et al.
Publicado: (2023)

PB1916: SOMATIC MUTATIONS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME IN RUSSIAN PATIENTS
por: Kohno, A., et al.
Publicado: (2022)

PB1996: CYTOGENETIC FEATURES OF 164 MOROCCAN PATIENTS WITH MYELODYSPLASTIC SYNDROME
por: Aghoutane, Yossra, et al.
Publicado: (2023)

PB1992: PROTEOMIC ANALYSIS REVEALS AUTOPHAGY INHIBITION IN MYELODYSPLASTIC SYNDROMES
por: Tsekoura, Georgia, et al.
Publicado: (2023)

PB2026: ROLE OF MOLECULAR PROFILING IN MYELODYSPLASTIC SYNDROME IN REAL-WORLD - A NEW APPROACH IN MYELODYSPLASTIC SYNDROME’S RISK STRATIFICATION?
por: Silva, Duarte Pacheco, et al.
Publicado: (2023)

PB1914: CYTOGENETIC FINDINGS IN 18 CHILDREN WITH MYELODYSPLASTIC SYNDROMES BY KARYOTYPIC AND FISH ANALYSIS
por: Manola, K., et al.
Publicado: (2022)

PB2029: ACQUIRED ALPHA THALASSEMIA IN ASSOCIATION WITH MYELODYSPLASTIC SYNDROME- A CASE REPORT
por: Balasubramanian, Priyavadhana, et al.
Publicado: (2023)

PB2011: TRANSFUSION BURDEN IS AN IMPORTANT PROGNOSTIC FACTOR IN LOWER-RISK MYELODYSPLASTIC SYNDROME
por: Lee, Jungmin, et al.
Publicado: (2023)

PB2013: THE FREQUENCY, EVOLUTION AND SIGNIFICANCE OF GENE MUTATION IN MYELODYSPLASTIC SYNDROMES WITH NORMAL KARYOTYPE
por: Xu, Feng, et al.
Publicado: (2023)

PB2049: MEXICAN REGISTRY OF MYELOPROLIFERATIVE NEOPLASMS. INITIAL REPORT
por: De La Peña Celaya, J. A., et al.
Publicado: (2022)

PB2022: ELTROMBOPAG IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A SINGLE-CENTER EXPERIENCE
por: Peña, Amaia Lopez, et al.
Publicado: (2023)

PB2001: PROGNOSTIC FACTORS IN MYELODYSPLASTIC SYNDROMES- A SWEDISH RETROSPECTIVE REAL-WORLD STUDY
por: Schain, Frida, et al.
Publicado: (2023)

PB2263: SUPPORTIVE CARE IN LOW-RISK MYELODYSPLASTIC SYNDROMES: ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS)
por: Cerchione, C., et al.
Publicado: (2022)

PB1923: PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH HYPOMETHYLATING AGENT USE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES
por: Zeidan, A., et al.
Publicado: (2022)

PB2012: DESCRIBING TREATMENT PATTERNS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ACCORDING TO IPSS-R RISK CATEGORY
por: Corry, Sorcha, et al.
Publicado: (2023)

PB2027: EFFICACY OF THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROME WITH UNFAVORABLE IMMUNOPHENOTYPIC AND CYTOGENETIC PROGNOSIS.
por: Trubkina, Hanna, et al.
Publicado: (2023)

PB1910: CHRONIC MYELOID LEUKEMIA AND RELATIONSHIP TO SECONDARY SOLID NEOPLASMS
por: Ramos, M. J., et al.
Publicado: (2022)

PB2218: CHILDHOOD MYELPROLIFERATIVE NEOPLASMS; A SINGLE CENTER EXPERIENCE
por: Ghali, Hasanein, et al.
Publicado: (2023)

PB2236: POPULATION BASED INCIDENCE OF ESSENTIAL THROMBOCYTHEMIA: AN ALBANIAN STUDY (2007-2021)
por: Perolla, Adela, et al.
Publicado: (2023)

PB1924: ARE WE TAKING ADVANTAGE OF THERAPEUTIC OPTIONS IN MYELODYSPLASTIC SYNDROME?-REAL WORLD DATA FROM HUNGARY
por: Miltényi, Z., et al.
Publicado: (2022)

PB2206: FULL SPECTRAL FLOW CYTOMETRY ANALYSIS OF THE BONE MARROW IMMUNE MICROENVIRONMENT IN PATIENTS WITH MYELODYSPLASTIC SYNDROME
por: chen, M., et al.
Publicado: (2022)

PB1917: PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF ELEMENTS OF THE ADAPTIVE IMMUNITY IN THE MICROENVIRONMENT OF MYELODYSPLASTIC SYNDROMES TREATED WITH 5-AZACITIDINE
por: Tsakiraki, Z., et al.
Publicado: (2022)

PB2041: EVALUATION OF THE PROGNOSTIC VALUE OF THROMBOPHILIA MARKERS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
por: Makarik, T., et al.
Publicado: (2022)

PB2054: HIP AND KNEE OSTEOARTHRITIS IN PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Holik, H., et al.
Publicado: (2022)

PB2053: PRIMARY ARTERIAL HYPERTENSION IN MYELOPROLIFERATIVE NEOPLASMS: A SYSTEMATIC REVIEW
por: Gaman, M.-A., et al.
Publicado: (2022)

PB2171: POTENTIAL ROLE OF FACTOR XII POLYMORPHISM IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
por: Efremova, Elizaveta, et al.
Publicado: (2023)

PB1912: MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND ASSOCIATED 5Q DELETION TO 13Q DELETION
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

PB1913: SYNERGISTIC EFFECTS OF DECITABINE AND APR-246 IN TP53 P.248Q-MUTATED MYELODYSPLASTIC SYNDROME
por: Fang, Y., et al.
Publicado: (2022)

PB2670: EQOL-MDS TRIAL: PATIENT-REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA.
por: Oliva, Esther, et al.
Publicado: (2023)

PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023)

PB1993: EXPRESSION OF NEO-201 MAY HELP IN THE DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
por: Duminuco, Andrea, et al.
Publicado: (2023)

PB2023: THE LEVEL OF VASCULAR ENDOTHELIAL FACTOR (VEGF) IN THE BLOOD SERUM OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS RAEB I).
por: Стародуб, Галина, et al.
Publicado: (2023)

PB2180: TREATMENT CHALLENGES OF COEXISTING MYELOID AND LYMPHOID NEOPLASM- A CASE REPORT
por: Smiljanic, Mihailo, et al.
Publicado: (2023)

PB2169: LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE COMBINATION THERAPY IN CONCOMITANT MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND MULTIPLE MYELOMA
por: Koh, Yu Han, et al.
Publicado: (2023)

PB2024: CLUSTERING OF COMORBIDITIES IS RELATED TO AGE AND SEX AND IMPACTS CLINICA1 OUTCOME IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE COHORT STUDY
por: Faiza, Talbi, et al.
Publicado: (2023)

PB2477: INTEGRATION OF OPTICAL GENOME MAPPING IN DAILY CYTOGENETICS LABORATORY ROUTINE.
por: Díaz González, Álvaro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h5o0ov65vqg8oi33m5j3ghmko7